Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
about
Vaccination for hepatitis C virus: closing in on an evasive targetCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesCost-effectiveness of Telaprevir combination therapy for chronic hepatitis CStatistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen designEmerging PEGylated drugs.Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1The hepatitis C cascade of care: identifying priorities to improve clinical outcomesThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.Hepatitis C: is a vaccine the solution?Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsEstimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis CThe cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional studyClinical impact of treatment timing for chronic hepatitis C infection: a decision modelNew protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysisHigh, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.SASLT practice guidelines: management of hepatitis C virus infection.Treating hepatitis C in the prison population is cost-saving.The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study.A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C.Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications.The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.The cost-effectiveness of boceprevir for hepatitis C.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator.Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.Is combination therapy for chronic hepatitis C toxic for cardiac function?Progression to cirrhosis in hepatitis C patients: an age-dependent process.Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran.Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
P2860
Q22305922-2066753B-D20F-4C7C-91D7-B8E22AF6E450Q28488762-EF4106C0-84AD-4182-9759-DBD9F4308ED7Q28540562-89EC21DC-246F-47EF-A819-316ABDDF3304Q30361685-61EC06BE-8BFB-418B-9C3C-11662A472B44Q33447691-820E00D4-F6A4-4DEE-B8E9-D96E0542891DQ33629561-BEBE26EB-9177-4718-9E0E-2840A96A46BAQ33632459-531B7ED9-498B-4127-B8CB-CAB4498BB55FQ33710740-286B2C31-7E9F-40AA-9334-7F26ACC7D415Q33834958-DEF1046F-101C-491B-AB75-F3AEE1B50D69Q34098870-824C6B3D-CBDF-4B85-86FF-D193B93973D3Q34227450-E264D21F-B0D7-47AC-B839-D51E5FF24C5BQ34290831-673B8997-97B1-4DCB-B224-94FF80255E83Q34735072-6B3B0122-39B6-4F4F-AE87-2509C8B652C4Q35031753-A6812FD8-C44D-4B96-945D-BE526B7C1C45Q35572125-53002C2A-C3B5-4F15-B433-AAF11C1C4D21Q35822155-5879E625-9280-497F-B1BE-B36F69FD80B0Q35889164-2DF70735-3C75-4437-B5F3-5FF20AC5DDD8Q36652084-C38DF6EA-F0C4-4092-A173-D0CC39A7E1E4Q36978998-B8CB2573-D2A9-44C4-805E-BC3606CAD271Q37019765-3C2EEA03-8E36-41F0-BF7A-FFA2B36E21AEQ37299503-645E2FAD-F39F-482F-8880-AD550C7EBD5FQ37663322-B7BB418D-11F5-49E8-ABA1-6C179291C806Q37763117-5A9F07B3-8A63-4D06-891A-2DEB2F0549FCQ37763157-03019912-418C-4531-B54C-B402B9C70D5FQ38179536-230441C0-51BF-49B2-A09E-59296AB11D24Q38202682-3879F420-2ADB-4939-B807-E38FE80A4941Q38800572-48A447C5-B868-4822-9C5A-95969DD20672Q40101753-F9937B47-3232-40A7-A303-40D996977E09Q40398050-4CB5A30E-0493-40F9-98A1-CADE9CB4628AQ40584662-4848D193-7F5B-47D2-804E-8A88B0927DFFQ40597591-8804EC54-D36A-4DEE-A036-95C3B3E179CAQ40677384-77443CA0-B7E5-4EEE-A6DA-D47132A406A9Q40931707-88773555-98BE-486F-AC09-504DB3A01805Q41207230-40CF555D-B9FF-440A-B0E5-D0AF83C13250Q41434717-120D4AB7-A2BC-41A3-9E94-FC899663B9E5Q41919051-2541715D-1CE8-45C9-8450-EDA3D8171562Q42129945-85A1D481-DF19-430E-975B-1919643B992AQ42168870-4B6F3B87-DF2B-4EEE-8187-35B6AB42400DQ42252742-451FE463-6CD5-423F-BDA2-967F31068615Q42272479-365C3F60-6EF1-466C-B683-2BA95AB093F4
P2860
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@ast
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@en
type
label
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@ast
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@en
prefLabel
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@ast
Cost effectiveness of interfer ...... ally mild chronic hepatitis C.
@en
P2093
P2860
P50
P356
P1433
P1476
Cost effectiveness of interfer ...... cally mild chronic hepatitis C
@en
P2093
P2860
P304
P356
10.1136/GUT.2005.064774
P407
P577
2005-06-30T00:00:00Z